Home Combat Arthritis Roche Spends $451 Million to Acquire Inflazome's NLRP3 Program

Roche Spends $451 Million to Acquire Inflazome's NLRP3 Program

Sep 28, 2020 comments off

Roche Spends $451 Million to Acquire Inflazome’s NLRP3 Program

The deal will provide the pharma giant with a unique new platform for tackling autoimmune diseases.

Read More…

You May Also Like

Another life-saving treatment is found for covid-19

Arthritis Drugs Reduced Covid-19 Deaths, ICU Time in Study

Critically ill Covid-19 patients to receive new potentially life-saving drugs – shropshirestar.com

The Best Apps for Rheumatoid Arthritis

Daily briefing: Two arthritis drugs cut the risk of death from COVID

Trial of COVID-19 blood plasma finds no benefit in severely ill patients – Reuters